This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
As one of the first partners of ATI, the biotechnology company hired interns to form a team of data stewards to work on a significant data segmentation project. The programs through ATI are customized to the companies they partner with, offering free technical training that aligns with the organizations skills needs.
Sana Biotechnology CEO Steve Harr cuts the ribbon at the company’s new manufacturing facility in Bothell, Wash., The Bothell facility will house Sana’s proprietary cancer drug program. The diabetes program involves turning stem cells into insulin-producing islet cells. Washington state Rep.
Sana Biotechnology has a new $50 million tool in its toolbox. Gene editing technology is a key component in developing engineered cells as medicines, and we are pleased to have the ability to use the Cas12b system as part of a number of our ex vivo engineered cell programs,” said Steve Harr , Sana’s president and CEO in a statement.
Adaptive Photo) — Mark Adams is stepping down as chief operating officer of Adaptive Biotechnologies , the company said today in a regulatory filing. Sana Biotechnology named two new research leaders. Members include: Sonoma co-founder Alexander Rudensky , chair of the immunology program at the Sloan Kettering Institute.
Sana Biotechnology , a young and fast-growing Seattle-based biotech, has chosen the San Francisco Bay Area as the site for its new biomanufacturing facility. The company currently has multiple pre-clinical programs but has not yet entered a product into clinical trials. (Sana Photo).
Chad Robins, left, is co-founder and CEO of Adaptive Biotechnologies, which he co-founded with his brother, Harlan Robins, right, the company’s chief scientific officer. Adaptive Biotechnologies Photo). Adaptive Biotechnologies is laying off 12% of its workforce, or about 100 employees, GeekWire has learned. “We
Seattle-based cell and gene therapy company Sana Biotechnology will reduce its workforce by 15%, according to a statement issued Tuesday. The company said it was shutting a program focused on heart failure and outlined reset priorities for other programs. Sana CEO Steve Harr. Sana Photo).
A biotech prize for turning chemicals into food On the biotechnology front, the Mars Society plans to offer an incentive prize for methods that use microbes to convert simple chemicals, such as methane or methanol, into food. “Ask it anything you want, and you get the answer in multiple personalities,” he said.
Adaptive co-founders Harlan (left) and Chad Robins on the plaza at the new Adaptive Biotechnology headquarters. After doubling its workforce during the pandemic, Adaptive Biotechnologies finally has room to grow. Harlan, former head of the the computational biology program at Fred Hutch, serves as chief scientific officer.
The latest piece in her reinvention story is Synchrony’s new Tech Apprenticeship for Artificial Intelligence, a full-time, 12-month program that balances on-the-job learning with instructor-led training, providing Chavarin with a pathway into one of the most coveted technology spaces despite her very nontraditional IT background.
The company, founded in 2011, began commercial operations in 2018 and now has partnerships with Merck, Xyphos Biotechnology, Alpha Cancer Technologies and several other drug companies. Three Washington state companies — Sana Biotechnology , Impel Neuropharma and Paymentus — have gone public with a traditional IPO this year.
Chad Robins, left, is co-founder and CEO of Adaptive Biotechnologies, which he co-founded with his brother, Harlan Robins, right, a theoretical physicist turned computational biologist who is the company’s chief scientific officer. Adaptive Biotechnologies Photo). Lance Solomon.
It has three clinical programs to treat gastrointestinal diseases including C. Lumen is led by Finrow, a former senior vice president at Adaptive Biotechnologies, and Chief Science Officer Jim Roberts , the former head of basic sciences at the Fred Hutchinson Cancer Research Institute. They co-founded the startup in 2017.
Founder pedigree: Kiem, who is director of the Stem Cell and Gene Therapy Program at the Fred Hutch, and Lieber, a professor with the UW’s Division of Medical Genetics, will be scientific co-founders of Ensoma. In 2019, Kiem gave a TEDxSeattle talk on the science involved.
Absci is the latest in a string of Washington state biotech startups to test the public markets — others including Impel Neuropharma, Sana Biotechnology, Athira Pharma, and Silverback Therapeutics have had IPOs in the past year. The amount of investment that is pouring into biotechnology and the life sciences is incredible,” said Alexandre.
based biotechnology company struck a deal with Merck in which the pharmaceutical powerhouse will provide a $600 million upfront payment and make a $1 billion equity investment to continue development of treatments for breast cancer. Seattle Genetics CEO Clay Siegall. Seattle Genetics Photo).
Under the agreement, Takeda has options to exclusively license programs at the preclinical stage and will take products to the clinic and through commercialization. Immusoft’s most advanced therapeutic program is designed to treat a rare enzyme deficiency disorder, Hurler syndrome.
“We realized that we may be on to a rapid response vaccine to the COVID-19, so we quickly accelerated that program forward,” said Deborah Fuller , a professor of microbiology and a vaccinologist. LION was developed by the Seattle biotechnology company HDT Bio; Amit P. Kandhar is the lead formulation developer of LION.
Healthcare Technology is paramount for the healthcare industry, including the medical, pharmaceutical, and biotechnology industries. In order to meet the growing demand for tech talent, companies such as Progressive have invested in internal upskilling bootcamp programs to help close the skills gap.
Quantum computing is at an exciting stage, where active collaboration between academia and industry is leading to rapid innovation, explains Mohit Pandey, a quantum computing scientist who has extensive experience using quantum computing for drug discovery while working in the biotechnology industry. Contact us today to learn more.
Cyrus Biotechnology has several drug discovery and development partnerships and also sells Cyrus Bench, a software platform for protein engineering. Seattle-based Cyrus Biotechnology is entering a protein engineering collaboration with Boston-based Selecta Biosciences that could pull in up to $1.5 Cyrus Photo). Cyrus CEO Lucas Nivon.
The technology was developed under DARPA’s Reliable Neural-Interface Technology (RE-NET) program , and offers new potential for safely expanding the use of brain-machine interfaces (BMIs) to treat physical disabilities and neurological disorders.
Local immunotherapy biotech companies include Umoja Biopharma, Sana Biotechnology, Chinook Therapeutics, Kineta, Alpine Immune Sciences, Adaptive Biotechnologies, and others.
A new genetic engineering approach overcomes this barrier, according to a report at the annual meeting of the International Society for Stem Cell Research by scientists at the University of Washington and Sana Biotechnology, a Seattle-based company. Murry’s research was conducted primarily at the UW, with financial support from Sana.
Sana Biotechnology raised $587 million in its IPO, Absci pulled in $200 million, and vaccine company Icosavax raised more than $180 million. The pandemic also led to growth of regional companies such as Adaptive Biotechnologies, which doubled its workforce during the pandemic as it supported vaccine development and built a COVID-19 test.
As a result, all business leaders are finding that their roles are expanding with opportunities to drive progressive digital-first programs. Through engaging with employees, leaders can better comprehend which specific processes or programs are hurting productivity and invest in solutions to close those gaps.
Two others Washington state biotech companies, Absci and Icosavax , have also recently filed to go public, building on IPOs earlier this year from Sana Biotechnology , Impel Neuropharma and Lyell Immunopharma, which is based in South San Francisco and the Seattle area. Eliem’s tech. Via SEC filing).
How many will be accepted into the program? Strella Biotechnology Co-founder and CEO Katherine Sizov won GeekWire’s Elevator Pitch startup competition at the 2022 GeekWire Summit, with a unique sensing technology that reduces food waste by determining what? Steuart Walton. GeekWire story: Scramble the fighters! Amazon’s Treasure Truck.
The program will start in November at the UW. (UW It will host a 9-month program this November for 20-to-25 companies in partnership with Microsoft and the University of Washington’s business, engineering, and computer science schools. “This is the track,” Dooley said.
In Washington state, Absci , Zymeworks , TwinStrand Biosciences , NanoString Technologies , Neoleukin Therapeutics and Sana Biotechnology all shed employees in 2022. Along with the layoffs, the company is de-prioritizing a program for glioblastoma and a discovery program for blood cancers.
Other former positions include leadership roles at the Gates Foundation and directing the global drug development program at PATH. Susan Wyrick of Sana Biotechnology. “It’s been a wonderful ride launching and leading this deep-tech startup mentorship program in Seattle for just over 3 years now.
This included the eight-week Family Tech Support Center program, funded by a Tableau Foundation grant, which assisted families with IT challenges and sought to maximize the impact of Amazon’s donation of 9,000 laptops to families. Seattle-based Adaptive Biotechnologies appointed Leslie Trigg and Katey Owen to its board of directors.
Workplace of the Year finalists, clockwise from top left: Adaptive Biotechnologies co-founders Harlan and Chad Robins; the Helion team; Impinj offices in Seattle; Treasury4 team; Blink CEO Karen Clark Cole. This year’s finalists are Adaptive Biotechnologies, Blink, Helion, Impinj and Treasury4. Blink Blink CEO Karen Clark Cole.
The program was shuttered “based on a review of the preliminary data, the expected benefit to risk ratio for patients, and recent developments in the field of IL-2 therapeutics,” according to a November company statement. IL-2 can quell cancer but it can also have toxic effects, which Neoleukin’s protein aimed to to minimize.
The category highlights pioneering health, life science, biotechnology or medical breakthroughs that hold great promise for bettering our lives or improving the healthcare system. A fifth company is the brainchild of a founder previously at Pacific Northwest Research Institute (PNRI).
There’s a fourth biotech company being born, said Olson, who also heads the Invent at Seattle Children’s Postdoctoral Scholars Program to train students underrepresented in science for careers in biotechnology. I think stepping back and not casting a founder shadow is really important.”
Andris Zoltners stepped down from the board of publicly traded Seattle-based Adaptive Biotechnologies after 11 years. . Nautilus Biotechnology Photo). Nautilus Biotechnology, a Seattle and Silicon Valley startup led by Isilon co-founder Suja Patel, hired Nick Nelson as chief business officer. Nick Nelson.
He’s now CEO of Nautilus Biotechnology, and he’s not taking any big chances in the current economic downturn. Earlier companies are considering fewer development programs and having a slower ramp on hiring. Neoleukin Therapeutics recently shed staff in the wake of disappointing clinical data for its lead program, for example.
Three Seattle-area companies — Sana Biotechnology , Impel Neuropharma, and Paymentus — have gone public with a traditional IPO this year, and Icosovax just filed last week. Last month Seattle-based Nautilus Biotechnology, led by Isilon Systems co-founder Sujal Patel, went public via a SPAC merger.
David Shoultz , formerly head of Neoleukin’s COVID-19 program, was tapped as COO and co-founder. The Monod team will use the funds to mature and expand its platform, generate new biosensors for additional targets in biotechnology and health, and build prototypes to detect targets in real-world applications. He didn’t have to look far.
The news is a bright spot for Seattle’s biopharma scene which has seen employee cuts at several biotech companies recently as part of wider layoffs in the industry, including at NanoString Technologies , Sana Biotechnology , Eliem Therapeutics and Neoleukin Therapeutics. It reported $19.3 billion in revenue for 2022, up from $18.5
In addition, Fred Hutchinson Cancer Center would oversee the clinical oncology programs at both the center and UW Medical Center, according to a press release. Under the new arrangement, all SCCA clinical sites would be renamed “Fred Hutchinson Cancer Center.”.
Seattle is known for its strength in cell therapy, notes Modulus chief scientist Max Darnell , with growing biotech companies such as Sana Biotechnology and Lyell Immunopharma, as well as an arm of Bristol Myers Squib. “We want to be this discovery player that can plug into these larger incumbents,” he said.
“This funding will allow us to build upon our promising preliminary data demonstrating detection of Alzheimer’s disease at its earliest stages and further our preclinical therapeutic program,” Daggett said in a statement. Before COVID-19, AltPrep was housed at the UW’s CoMotion Labs incubator space in Fluke Hall.
We organize all of the trending information in your field so you don't have to. Join 83,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content